Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
April 25 2022 - 08:00AM
GlobeNewswire Inc.
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology
company pioneering a differentiated approach to treating cancer and
neurodegenerative disease through the inhibition of SEMA4D, today
announced that it has been
selected for poster presentation
related to its ActivMAb technology platform during
the upcoming 18th Annual PEGS
Boston Conference & Expo, taking place from May 2nd to
May 6th via in person and virtual attendance.
“We look forward to sharing these new data
demonstrating expression of complex multi-pass membrane receptors
presented in their native conformation. These receptors are an
important class of pharmaceutical targets including ion channels
and GPCR, to which it has proved very difficult to select
antibodies employing other existing technologies. Using our
ActivMAb technology, we have successfully selected potent
antibodies specific for these targets, such as chemokine receptor
CXCR4 and SARS-CoV2 receptor.” said Ernest Smith, Ph.D., Chief
Scientific Officer of Vaccinex.
Details are shown below: |
Abstract title: |
Native complex membrane antigen expression on poxvirus for antibody
discovery, P161 |
Presenter: |
Angelica Cornelison, BD & Alliance Management, Vaccinex |
Session: |
Engineering Stream, Display of Biologics |
Date: |
May 2-3, 2022 |
Venue: |
Hynes Convention Center, Boson, MA, USA |
Access: |
The Poster will be presented in-person and will also be available
on Vaccinex’s website starting on May 2 at 3:50 PM EST. |
|
|
Add to calendar: |
https://ir.vaccinex.com/presentations |
Program Link: |
https://www.pegsummit.com/?_ga=2.211247765.1460103379.1650565287-290157728.1650307327# |
Vaccinex’s proprietary technology allows
efficient expression of isolated and properly folded multi-pass
transmembrane receptors in the extracellular envelope of poxvirus.
More than one third of all FDA approved drugs target such receptors
but, because these complex proteins cannot be purified from the
natural cellular membranes in which they are embedded without
destroying their conformation and activity, it has not been
possible to select antibody drugs except in very few cases. As
methods for identifying promising therapeutic targets become more
powerful, biopharma is increasingly turning its attention to the
unmet need for antibodies to this important class of targets. Using
a method that embeds the protein of interest in a cell derived
viral membrane, these target proteins are expressed in their
natural conformation. The resulting antigen expressing virus can be
readily purified and used for antibody selection employing any in
vitro antigen display or immunization platform. This is a novel
enabling technology for antibody drug discovery and development
projects.
About ActivMAb®Vaccinex has
developed a proprietary mammalian cell-based antibody discovery
platform with unique multi-pass membrane target capabilities. The
ActivMAb technology now has four main applications: complex
membrane antigen presentation, antibody or antigen discovery, and
protein optimization. Vaccinex has entered into an antibody license
with Surface Oncology (Cambridge, MA) and into Material Transfer
Agreements for drug discovery or process development with two major
pharma utilizing this technology. Vaccinex seeks partnering
opportunities for co-development or licensing of existing
antibodies in our pipeline, discovery of new antibodies and/or
applications for this powerful
technology.
About Vaccinex, Inc. Vaccinex,
Inc. is pioneering a differentiated approach to treating
cancer and slowly progressive neurodegenerative diseases through
the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug
candidate, pepinemab, blocks SEMA4D, a potent biological effector
that it believes prevents immune infiltration into tumors and
triggers inflammation in chronic diseases of the brain. Pepinemab
is being evaluated in a Phase 1b/2 study in recurrent or metastatic
head and neck cancer and a Phase 1/2a study in Alzheimer’s Disease,
with ongoing exploration of potential Phase 3 development in
Huntington’s disease. The Company additionally intends to leverage
its proprietary drug discovery platform, ActivMAb, to create
strategic collaborations, particularly by exploiting its unique
capability to select high value antibodies against important
multi-pass membrane receptors.
Forward Looking StatementsTo
the extent that statements contained in this presentation are not
descriptions of historical facts regarding Vaccinex, Inc.
(“Vaccinex,” “we,” “us,” or “our”), they are forward-looking
statements reflecting management’s current beliefs and
expectations. Such statements include, but are not limited to,
statements about our plans, expectations and objectives with
respect to the results and timing of our clinical trials of
pepinemab in various indications, the use and potential benefits of
pepinemab in Huntington’s and Alzheimer’s disease and other
indications, and other statements identified by words such as
“may,” “will,” “appears,” “expect,” “hope”, “planned,”
“anticipate,” “estimate,” “intend,” “hypothesis,” “potential,”
“suggest”, “advance,” and similar expressions or their negatives
(as well as other words and expressions referencing future events,
conditions, or circumstances). Forward-looking statements involve
substantial risks and uncertainties that could cause the outcome of
our research and pre-clinical development programs, clinical
development programs, future results, performance, or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, uncertainties inherent in the execution, cost and
completion of preclinical and clinical trials, uncertainties
related to regulatory approval, risks related to our dependence on
our lead product candidate pepinemab, the impact of the COVID-19
pandemic, and other matters that could affect our development plans
or the commercial potential of our product candidates. Except as
required by law, we assume no obligation to update these
forward-looking statements. For a further discussion of these and
other factors that could cause future results to differ materially
from any forward-looking statement, see the section titled “Risk
Factors” in our periodic reports filed with the Securities and
Exchange Commission (“SEC”) and the other risks and uncertainties
described in the Company’s most recent year-end Annual Report on
Form 10-K and subsequent filings with the
SEC.
Contact us for unique solutions to
assist in your Drug Discovery and Development
projects: Angelica
Cornelison Vaccinex,
Inc activmab@vaccinex.com
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to May 2023
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From May 2022 to May 2023